Mostrar el registro sencillo del ítem

dc.contributor.authorCueto Sánchez, Alejandro José
dc.contributor.authorDi Zeo-Sánchez, Daniel Enrique
dc.contributor.authorSegovia-Zafra, Antonio
dc.contributor.authorMatilla-Cabello, Gonzalo
dc.contributor.authorBodoque-García, Ana
dc.contributor.authorLucena-González, María Isabel 
dc.contributor.authorVillanueva-Paz, Marina
dc.date.accessioned2025-03-20T10:36:39Z
dc.date.available2025-03-20T10:36:39Z
dc.date.issued2023-04-26
dc.identifier.citationCueto-Sánchez A, Di Zeo-Sánchez DE, Segovia-Zafra A, Matilla-Cabello G, Bodoque-Garcí�a A, Lucena MI, et al. Immunophenotyping to improve the mechanistic understanding of idiosyncratic drug-induced liver injury: clinical implications and future directions. Explor Dig Dis. 2023;2:56–76. https://doi.org/10.37349/edd.2023.00018es_ES
dc.identifier.urihttps://hdl.handle.net/10630/38177
dc.description.abstractThe late event onset of a fraction of idiosyncratic drug-induced liver injury (DILI) cases and the link observed by genome-wide association studies (GWASs) of certain human leucocyte antigen (HLA) alleles with DILI due to specific drugs support the crucial role of the immune system (both innate and adaptive) in the pathogenesis of DILI. Recent advances in both flow and mass cytometry have allowed the profiling of all major immune cell types in a given sample. Therefore, determining the lymphocyte populations in samples from patients with DILI would facilitate the development of specific biomarkers for DILI diagnosis and prognosis. To date, a few studies have explored the immune landscape in DILI. In a recent study of leukocyte immunophenotyping using flow cytometry from the Spanish DILI Registry, an important role of adaptive immune response in DILI is suggested. DILI patients had significantly higher levels of T helper 1 (Th1) cells and activated helper and cytotoxic T cells than healthy controls. Furthermore, the increased expression of negative immune checkpoints and ligands in DILI patients could reflect a restoration of the immune homeostasis. Differences in the profile of cytokines in DILI patients from the Drug-Induced Liver Injury Network (DILIN) also suggest an involvement of both innate and adaptive immune systems in DILI development and prognosis. Moreover, several studies based on immunophenotyping of liver infiltrates showed a distinctive pattern of cellular infiltrates in patients with immune checkpoint inhibitors (ICIs)-DILI, with lower levels of plasma cells, CD20+ B cells and CD4+ T cells than in autoimmune hepatitis (AIH) patients. These pioneering studies highlight the importance of immunophenotyping for the mechanistic understanding of DILI. In this review, available data on immunophenotyping in DILI are gathered, and the potential clinical applications of cutting-edge, novel immunophenotyping techniques are discussed.es_ES
dc.description.sponsorshipThis work was supported by grants from the Instituto de Salud Carlos III cofounded by Fondo Europeo de Desarrollo Regional (FEDER), contract numbers: [PI21/01248], [PI19-00883], [PT 20/00127], [UMA18-FEDERJA-194], [PY18-3364]; and grants from Consejería de Salud de Andalucía cofounded by FEDER, contract number: [PEMP-0127-2020]. Marina Villanueva-Paz holds a Sara Borrell [CD21/00198] research contract from Instituto de Salud Carlos III (ISCIII) and Consejería de Salud de Andalucía.es_ES
dc.language.isoenges_ES
dc.publisherOpen Explorationes_ES
dc.rightsAttribution 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHepatotoxicidades_ES
dc.subjectHígado - Efectos de los medicamentoses_ES
dc.subjectHígado - Enfermedadeses_ES
dc.subjectInmunodiagnósticoes_ES
dc.subjectDiagnóstico de laboratorioes_ES
dc.subject.otherHepatotoxicityes_ES
dc.subject.otherDrug-induced liver injury (DILI)es_ES
dc.subject.otherImmune tolerancees_ES
dc.subject.otherImmune systemes_ES
dc.subject.otherImmunophenotypinges_ES
dc.subject.otherDiagnosises_ES
dc.subject.otherMechanismses_ES
dc.titleImmunophenotyping to improve the mechanistic understanding of idiosyncratic drug-induced liver injury: clinical implications and future directionses_ES
dc.typejournal articlees_ES
dc.centroFacultad de Medicinaes_ES
dc.identifier.doi10.37349/edd.2023.00018
dc.type.hasVersionVoRes_ES
dc.departamentoFarmacología y Pediatríaes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem